Intellia Therapeutics News - September 8, 2026
Intellia's CRISPR Therapy Lonvo-z Granted FDA Priority Review for Hereditary Angioedema
Intellia Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for lonvoguran ziclumeran...
Intellia Gains FDA Priority Review for World’s First In Vivo CRISPR Therapy
Intellia Therapeutics announced the FDA accepted its Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z). The agency granted Priority...
🟢 Intellia Therapeutics is trading 5% up in pre-market after announcing a $400 million non-dilutive loan facility
Intellia Therapeutics is trading $13.39 (+5.10%) after announcing a $400 million non-dilutive senior secured loan facility with OrbiMed. - $75 million was...